Telaglenastat Hydrochloride

Phase 2Small molecule

Telaglenastat Hydrochloride is one of 102 small molecule programs targeting Recurrent Multiple Myeloma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Multiple MyelomaActive, not recruiting

Advanced Lung Non-Small Cell CarcinomaActive, not recruiting

Advanced Malignant Solid NeoplasmActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Recurrent Multiple MyelomaPhase 1

Active, not recruiting

Advanced Lung Non-Small Cell CarcinomaPreclinical

Active, not recruiting

Advanced Malignant Solid NeoplasmPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Taxotere

AAvyxa

Phase 3

229 2

Tuoyi

SSun Yat-sen University

Phase 3

8 3

TY-9591

TTYK Medicines, Inc

Phase 3

2 4

Telaglenastat Hydrochloride

NNational Cancer Institute (NCI)

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Non-Small Cell Lung Cancer

NCT04250545

Phase 1Active, not recruiting

Astrocytoma, IDH-Mutant, Grade 2

NCT03528642

Q1 2027

PreclinicalActive, not recruiting

Advanced Lung Non-Small Cell Carcinoma

NCT03831932

Q2 2027

Phase 2Active, not recruiting

Advanced Malignant Solid Neoplasm

NCT03872427

Q3 2027

Phase 1Active, not recruiting

Recurrent Multiple Myeloma

NCT03798678

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04250545·22 enrolled

Advanced Lung Non-Small Cell Carcinoma1 trial

A Phase Ib Study of Osimertinib (AZD9291) and Telaglenastat (CB-839) HCl in Patients With EGFR Mutant Non-Small Cell Lung Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT03831932·22 enrolled

Astrocytoma, IDH-Mutant, Grade 21 trial

A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03528642·40 enrolled

Advanced Malignant Solid Neoplasm1 trial

A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03872427·54 enrolled

Recurrent Multiple Myeloma1 trial

Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination With Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03798678·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Telaglenastat Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Telaglenastat Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Telaglenastat Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

Telaglenastat Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Advanced Lung Non-Small Cell Carcinoma1 trial

Astrocytoma, IDH-Mutant, Grade 21 trial

Advanced Malignant Solid Neoplasm1 trial

Recurrent Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News